SCHEMBL25535241

SCHEMBL25535241

c1ccc(-c2nc(-c3ccccc3-c3ccccc3)cc(-c3ccc(-c4cc(-c5ccc6c(c5)-c5ccccc5C6(c5ccccc5)c5ccccc5)cc(-c5cccc6ccccc56)c4)c4ccccc34)n2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.34
ALDH1A1 P00352 3/20 0.34
HPGD P15428 3/20 0.34
KDM4E B2RXH2 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
TP53 P04637 1/20 0.34
TSHR P16473 1/20 0.34
NFKB1 P19838 1/20 0.34
MAPK1 P28482 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
ATM Q13315 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA9 Q16790 2/20 0.34
MEN1 O00255 5/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25535235 0.96 MAPT (0.36) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25534952 0.96 ALDH1A1 (0.36) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535227 0.95 PDK2 (0.36) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535242 0.94 MEN1 (0.38) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535239 0.94 MEN1 (0.37) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535090 0.94 MAPT (0.37) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535096 0.94 MEN1 (0.35) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535051 0.94 CA12 (0.39) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535247 0.93 CYP1A1 (0.33) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535143 0.93 MEN1 (0.39) MAPTALDH1A1HPGDKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-01 US disclosed
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE PIEZO1, LEF1, L1CAM MAPT 1595/4885ALDH1A1 254/4885HPGD 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.